RTOG 9003: Legacies of a landmark trial

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 2, 2014, Pages 253-254

  Trotti, Andy ^a,b   Machtay, Mitchell ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); EDITORIAL; HEAD AND NECK CANCER; HEALTH CARE QUALITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; PAPILLOMAVIRUS INFECTION; RADIATION DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; ONCOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84908174370     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.07.022     Document Type: Editorial

References (11)

1. Feigenberg S, Patel K, Amdur RJ, Mendenhall WM. RTOG 9003: The untold story. Int J Radiat Oncol Biol Phys 2014;90:251-252.
2. N. Foray Claudius Regaud (1870-1940): A pioneer of radiobiology and radiotherapy Cancer Radiother 16 2012 315 321
3. V.A. Marcial, T.F. Pajak, and C. Chang Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (Preliminary report) by the Radiation Therapy Oncology Group (RTOG) Int J Radiat Oncol Biol Phys 13 1987 41 47
4. J.D. Cox, T.F. Pajak, and V.A. Marcial Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: Preliminary report of Radiation Therapy Oncology Group protocol 83-13 Red 18 1990 515 521
5. Trotti A, Zhang Q, Bentzen SM, et al. Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512). Int J Radiat Oncol Biol Phys 2014;89:958-963.
6. B.S. Chera, R.J. Amdur, and C.G. Morris T1n0 to T2n0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy Int J Radiat Oncol Biol Phys 78 2010 461 466
7. H.E. Newlin, R.J. Amdur, and C.E. Riggs Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer Cancer 116 2010 4533 4540
8. J. Bourhis, J. Overgaard, and H. Audry Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis Lancet 368 2006 843 854
9. J. Overgaard, H.S. Hansen, and L. Specht Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial Lancet 362 2003 933 940
10. Network NCC. NCCN guidelines, 2014.
11. Trotti A, Gillison ML. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer, vol. 2013. Radiation Therapy Oncology Group, 2013; RTOG 1016 protocol.